<DOC>
	<DOCNO>NCT01527045</DOCNO>
	<brief_summary>This phase II trial study well donor atorvastatin treatment work prevent severe graft-versus-host disease ( GVHD ) nonmyeloablative peripheral blood stem cell ( PBSC ) transplant patient hematological malignancy . Giving low dos chemotherapy , fludarabine phosphate , donor PBSC transplantation slow growth cancer cell may also prevent patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also cause immune response body 's normal cell ( GVHD ) . Giving atorvastatin donor transplant may prevent severe GVHD .</brief_summary>
	<brief_title>Donor Atorvastatin Treatment Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant Patients With Hematological Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess whether 2 week donor statin treatment reduces risk severe acute GVHD . SECONDARY OBJECTIVES : I . To assess whether 2 week statin treatment normal PBSC donor feasible , tolerable safe . OUTLINE : DONOR : Donors receive atorvastatin orally ( PO ) daily ( QD ) begin day -14 continue last day stem cell collection . NONMYELOABLATIVE PREPARATIVE REGIMEN : If patient enrol investigational nonmyeloablative hematopoietic cell transplant ( HCT ) protocol treatment plan use nonmyeloablative preparative regimen postgrafting cyclosporine ( CSP ) use acute GVHD primary endpoint , preparative regimen immunosuppression transplant accord respective protocol treatment plan ( Protocol 2546 serve adjunct protocol ) . If patient enrol investigational nonmyeloablative HCT protocol treatment plan use nonmyeloablative preparative regimen , Protocol 2546 serve independent primary treatment protocol . The preparative regimen immunosuppression transplant follow : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 ( except patient prior autologous HCT equivalent high-dose therapy without HCT ) undergo low-dose total body irradiation ( TBI ) day 0 . TRANSPLANT : Patients undergo donor PBSC transplant day 0 . POST-GRAFTING IMMUNOSUPPRESSION : Patients receive CSP PO twice daily ( BID ) day -3 +56 taper day +180 . Patients also receive mycophenolate mofetil ( MMF ) PO BID IV every 12 hour day 0-27 . After completion study treatment , patient follow 1 year annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>IF PROTOCOL 2546 SERVES AS AN ADJUNCT PROTOCOL , THE PATIENTS ONLY NEEDS TO MEET INCLUSION CRITERIA 1 THROUGH 5A Availability human leukocyte antigen ( HLA ) identical sibling donor Transplantation PBSC CSPbased postgrafting immunosuppression Willingness give inform consent Patient enrol investigational nonmyeloablative HCT protocol nonmyeloablative treatment plan postgrafting CSP use acute GVHD primary endpoint ( protocol 2546 serve adjunct protocol ) ; OR Patient enrol investigational nonmyeloablative HCT protocol , case protocol 2546 serve independent primary treatment protocol patient must meet following inclusion exclusion criterion : Patients must hematologic malignancy treatable nonmyeloablative HCT ; follow disease permit although diagnosis consider approve Patient Care Conference ( PCC ) principal investigator : Aggressive nonHodgkin lymphoma ( NHL ) histologies diffuse large Bcell NHL eligible autologous HCT , eligible highdose allogeneic HCT , fail autologous HCT Mantlecell NHL may treat first complete remission ( CR ) ; ( diagnostic lumbar puncture [ LP ] require pretransplant ) Low grade NHL &lt; 6 month duration CR course conventional therapy Chronic lymphocytic leukemia ( CLL ) must either : Failed meet National Cancer Institute ( NCI ) Working Group criteria complete partial response therapy regimen contain fludarabine phosphate ( FLU ) ( another nucleoside analog ) experience disease relapse within 12 month complete therapy regimen contain FLU ( another nucleoside analog ) Failed FLUcyclophosphamide ( CY ) Rituximab ( FCR ) combination chemotherapy time point ; Have `` 17p deletion '' cytogenetic abnormality ; patient receive induction chemotherapy could transplant 1st CR Patients diagnosis CLL ( small lymphocytic lymphoma ) progress prolymphocytic leukemia ( PLL ) ; Patients Tcell CLL PLL Hodgkin lymphoma must receive failed frontline therapy Multiple myeloma must receive prior chemotherapy ; consolidation chemotherapy autografting prior nonmyeloablative HCT permit Acute myeloid leukemia ( AML ) must &lt; 5 % marrow blast time transplant Acute lymphocytic leukemia ( ALL ) must &lt; 5 % marrow blast time transplant Chronic myeloid leukemia ( CML ) Patients accept show intolerance tyrosine kinase inhibitor beyond first chronic phase ( CP1 ) receive previous myelosuppressive chemotherapy HCT , &lt; 5 % marrow blast time transplant Myelodysplasia ( MDS ) /myeloproliferative syndrome ( MPS ) Patients must &lt; 5 % marrow blast time transplant Waldenstrom 's macroglobulinemia must fail 2 course therapy Patients &lt; 12 year age must approve principal investigator relevant patient review committee , Fred Hutchinson Cancer Research Center ( FHCRC ) Patient Care Conference ( PCC ) Patients must either relapse previous highdose chemotherapy autologous allogeneic HCT , else ineligible approach due age , failure mobilize sufficient hematopoietic stem cell , medical comorbidities , patient refusal Patients refuse treat conventional autologous allogeneic HCT protocol DONOR GROUP A : Age &gt; = 18 year DONOR GROUP A : HLA genotypically identical sibling DONOR GROUP A : Willingness give informed consent DONOR GROUP B : Age &gt; = 18 year DONOR GROUP B : HLA genotypically identical sibling DONOR GROUP B : Willingness give informed consent IF PROTOCOL 2546 SERVES AS AN ADJUNCT PROTOCOL , THE PATIENT ONLY NEEDS TO MEET EXCLUSION CRITERIA 1 THROUGH 3 Myeloablative preparative regimen Participation investigational study acute GVHD primary endpoint The allogeneic PBSC donor contraindication statin treatment Patients eligible willing receive potentially curative highdose chemotherapy autologous HCT Cardiac ejection fraction &lt; 30 % multi gated acquisition scan ( MUGA ) scan cardiac echocardiogram ( echo ) active symptomatic coronary artery disease ; patient cardiac disease evaluate appropriate cardiac study and/or cardiology consultation clinically indicate Corrected diffusion capacity lung carbon monoxide ( DLCO ) &lt; 40 % predict , total lung capacity ( TLC ) &lt; 30 % predict , forced expiratory volume one second ( FEV1 ) &lt; 30 % predict , receive continuous supplementary oxygen Patients clinical laboratory evidence liver disease evaluate conjunction gastrointestinal ( GI ) consult service cause liver disease , clinical severity , degree portal hypertension ; patient exclude find fulminant liver failure , cirrhosis liver evidence portal hypertension , bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , refractory ascites related portal hypertension , bacterial fungal liver abscess , chronic viral hepatitis total serum bilirubin &gt; 3mg/dl , actively symptomatic biliary disease Patients renal failure eligible ; however , patient preexist renal insufficiency likely compromise renal function may require dialysis Patients seropositive human immunodeficiency virus ( HIV ) Women pregnant breastfeed Fertile men woman unwilling use contraception HCT 12 month afterward Patients active nonhematological malignancy ( except nonmelanoma skin cancer ) nonhematological malignancy ( except nonmelanoma skin cancer ) render evidence disease , great 20 % chance disease recurrence within 5 year ; exclusion apply patient nonhematologic malignancy require therapy Karnofsky score &lt; 60 adult patient Lanskyplay performance score &lt; 50 pediatric patient Patients fungal pneumonia radiological progression receipt amphotericin formulation moldactive azoles great 1 month DONOR GROUP A : Age &lt; 18 year DONOR GROUP A : History liver disease ; donor history liver disease would eligible serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2 time upper limit normal ( ULN ) DONOR GROUP A : History myopathy DONOR GROUP A : Hypersensitivity atorvastatin DONOR GROUP A : Pregnancy DONOR GROUP A : Nursing mother DONOR GROUP A : Current serious systemic illness DONOR GROUP A : Concurrent treatment strong inhibitor hepatic cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP 3A4 ) ( i.e . clarithromycin , erythromycin , protease inhibitor , azole antifungal ) DONOR GROUP A : Failure meet local criterion stem cell donation DONOR GROUP A : Total creatinine kinase &gt; 2 time ULN DONOR GROUP B : Age &lt; 18 year DONOR GROUP B : History liver disease ; donor history liver disease would eligible serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2 time upper limit normal ( ULN ) DONOR GROUP B : History myopathy DONOR GROUP B : Hypersensitivity atorvastatin DONOR GROUP B : Pregnancy DONOR GROUP B : Nursing mother DONOR GROUP B : Current serious systemic illness DONOR GROUP B : Concurrent treatment strong inhibitor hepatic cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP 3A4 ) ( i.e . clarithromycin , erythromycin , protease inhibitor , azole antifungal ) DONOR GROUP B : Current use statin drug DONOR GROUP B : Failure meet local criterion stem cell donation DONOR GROUP B : Total creatinine kinase &gt; 2 time ULN</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>